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Osteoarthritis and Cartilage 23 (2015) 1823e1824EditorialInﬂammation in osteoarthritis: changing viewsDecades ago, osteoarthritis (OA)was considered as the sole conse-
quence of a “tear and wear” process of cartilage without any partici-
pation of joint cells from any joint tissues. This hypothesis was
based on the known risk factors for OA, all involving, at least in
part, a mechanical aspect like trauma, joint deformation, ageing
(with a life-long repetitive mechanical stress on joints), and obesity
(forweight bearing joints).Moreover, in the past deﬁnition of inﬂam-
mation, rednesswasmandatory, a feature not possible in OA because
cartilage is a non-vascularized tissue. The revolution to considerOAas
the consequence of cellular events and not as a passive process came
in the 1970's when researchers succeeded to culture chondrocytes,
the only cell type present in cartilage1. Thanks to fantastic advances
inmolecular biology, a coupleof pioneersﬁrst showed that these cells
were able to participate to the homeostasis of the cartilagematrix but
also, in certain circumstances, to secrete soluble mediators known to
be proinﬂammatory in other tissues, like prostaglandins and
cytokines2e6. These discoveries opened the door to the exciting
research area of the role of inﬂammation in OA. The fascinating
studies and reviews published in this supplement issue of Osteoar-
thritis and Cartilage highlight howmuch this ﬁeld has accomplished
since then. From pathophysiology to biomarkers, from genetics to
treatments, inﬂammation has spread to all topics in OA.
Synovitis is a frequent feature observed inOA althoughwedonot
have a clear understanding on why the inﬂammation is heteroge-
neous in this disease7. Anyway, it is not merely a reﬂection of dam-
age but contributes to the OA process, since depletion of synovial
liningmacrophagesmarkedly diminishes joint pathology inmurine
OA8. Moreover, synovial cells express high levels of alarmins such as
S100A8 and -9, which were long seen as markers of inﬂammation.
Recently, it became clear that theyare inﬂammatory anddestructive
mediators per se, andmurineOApathology is diminished in S100A8/
9 knockout mice9. We will learn more on these processes thanks to
the studies published in this special issue ofOsteoarthritis andCarti-
lage, involving experiments on synovial ﬂuid, synovial tissue but
also subchondral bone coming from OA patients. IL10, IL17, IL22,
IL1-RA are examples of cytokines explored here.
The ﬁeld of wet biomarkers (as opposed to imaging biomarkers)
for prognostic use is making huge progress with the assessment in
plasma and synovial ﬂuid of inﬂammatory mediators levels such as
IL6, TNF or IL1RA as exempliﬁed in other studies presented in this
issue.
Although the OA research community agrees that genetics and
epigenetics play a critical role in the pathophysiology of OA, the
complexity of the disease makes the research in the ﬁeld complexhttp://dx.doi.org/10.1016/j.joca.2015.09.012
1063-4584/© 2015 Osteoarthritis Research Society International. Published by Elsevier Las well10. However, we will see in this issue that inﬂammation-
related genes are good candidates and deserve our attention.
One of the main clinical features of OA and probably the most
important for a patient is pain. But why, for the same level of carti-
lage degradation, one patient is painful whereas the other one is
not remains to answered. Novel studies published in this issue
and based on innovative experimental models should help us to
understand the role of some inﬂammatory pain mediators like
NGF or the amino-acid glutamate.
Basedonepidemiological studies showing thatobesitydoubles the
riskofhandOA11, the roleof adipokines, cytokinesproducedby thead-
ipose tissue and released into the blood ﬂow to participate in a low-
grade inﬂammationprocess,has beenwidely studied in thepastyears.
Moreover, obese patients with metabolic disturbances like diabetes
have a higher incidence and a more severe disease than non-
metabolic OA patients12. Interestingly, these discoveries have opened
our eyes to the fact that independent pathways could lead to different
OA phenotypes13. Thus, it makes sense to consider that the pathways
leading to post-trauma OA are not the same as metabolic syndrome-
associated OA or age-related OA, thus forming three main OA pheno-
types. A signiﬁcant amount of new results are revealed in this issue,
helping us to begin to delineate the different OA phenotypes. A better
understanding of OA phenotypes is of eminent importance for ther-
apy, since different subtypes of OAmay deserve different treatments.
As an example, ample studies with seeded chondrocytes or stem cells
have attempted to repair cartilage lesions with a focus on the lesion
itself,with variable success. Now it is becoming clear that the environ-
ment, including active synovial inﬂammation may prevent adequate
cartilage repair and needs attention as well. Intriguingly, stem cells
can be anti-inﬂammatory and it is argued that efﬁcacy of therapy de-
pends on intervention with smoldering synovial activation rather
than advanced tissue repair. Local stem cell therapy is successful in in-
ﬂammatory subtypes of murine OA14.
Taken together, this issue contains years and years of work from
junior and senior researchers and hours and hours from indepen-
dent expert manuscript reviewers, all of them having trusted our
Journal for disseminating their discoveries. We would like to thank
you for this conﬁdence and do hope that our readers will enjoy
reading this outstanding issue on Inﬂammation in osteoarthritis.
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